<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00012168</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068489</org_study_id>
    <secondary_id>NYU-9917</secondary_id>
    <secondary_id>NCI-G01-1915</secondary_id>
    <nct_id>NCT00012168</nct_id>
  </id_info>
  <brief_title>Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat</brief_title>
  <official_title>Lymphoscintigraphy Assisted Molecular Staging of Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University School of Medicine</source>
  <brief_summary>
    <textblock>
      RATIONALE: New imaging procedures such as lymphoscintigraphy may improve the ability to
      detect the spread of mouth and throat cancer to lymph nodes in the neck.

      PURPOSE: Pilot study of lymphoscintigraphy followed by sentinel lymph node mapping and
      sentinel lymph node biopsy to detect lymph node metastases in the neck in patients who have
      mouth or throat cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Evaluate the sensitivity of lymphoscintigraphy and isosulfan blue in localization of
           sentinel lymph nodes in patients with previously untreated squamous cell carcinoma of
           the oral cavity or oropharynx.

        -  Determine evidence of micrometastases in histologically normal sentinel lymph nodes
           resected from these patients.

        -  Assess the clinical significance of micrometastases in lymph nodes resected from these
           patients.

      OUTLINE: Patients undergo preoperative lymphoscintigraphy utilizing technetium Tc 99m sulfur
      colloid followed by intraoperative injections of isosulfan blue at 3-4 locations into the
      primary tumor periphery. Once the afferent lymphatic channel and sentinel node have been
      identified, patients undergo cervical lymphadenectomy followed by resection of the primary
      tumor.

      Resected primary tumor, radioactive lymph nodes, and blue-stained sentinel nodes are then
      subjected to molecular (polymerase chain reaction) and histocytochemical
      (immunohistochemistry for cytokeratin and micrometastases, light microscopy) analyses.

      Patients are followed at 1, 3, 6, 12, 18, and 24 months.

      PROJECTED ACCRUAL: Approximately 25 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1999</start_date>
  <primary_completion_date type="Actual">July 2003</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isosulfan blue</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lymphangiography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radionuclide imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sentinel lymph node biopsy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>technetium Tc 99m sulfur colloid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary squamous cell carcinoma of the oral cavity or
             oropharynx

               -  Stage 0-IVA (Any T, N0)

          -  No low-risk tumors

          -  Must require elective staging neck dissection and resection of primary tumor

        PATIENT CHARACTERISTICS:

        Age:

          -  18 to 70

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Other:

          -  Not pregnant or nursing

          -  No concurrent impaired mental status

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy

        Surgery:

          -  See Disease Characteristics

          -  No prior surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moni A. Kuriakose, MD</last_name>
    <role>Study Chair</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU School of Medicine's Kaplan Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 10, 2016</last_update_submitted>
  <last_update_submitted_qc>March 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage 0 oropharyngeal cancer</keyword>
  <keyword>stage 0 lip and oral cavity cancer</keyword>
  <keyword>stage I squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage I squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Technetium Tc 99m Sulfur Colloid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

